Surgery is the standard treatment for primary kidney cancer, however, in some cases surgery is either not possible or other health problems make surgery high risk. This study involves a relatively new, highly precise multidirectional radiotherapy technique called Stereotactic Ablative Body Radiotherapy (SABR) and all participants will receive this radiotherapy technique. The aim of the study is to test the ability of this technique to control the cancer within the kidney for those people where surgery is not an option, as well as to examine the side effects of the treatment, including how it may affect your kidney’s function.
Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
Closing Date of Accrual
2nd March 2020
A/Prof Shankar Siva, Peter MacCallum Cancer Centre, VIC
Clinical Trial Registration
After a hiatus from in-person events due to COVID-19
The RAVES trial treating prostate cancer Participating in a
For over 30 years, TROG Cancer Research has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.
Keep up to date with TROG news, subscribe to our community newsletter.